Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
The weak economy of the past four years combined with cutbacks due to mergers and acquisitions have helped consolidate U.S. biopharma activity further within the nation’s largest life sciences clusters. Yet that has not stopped several other regions from trying to carve out their own piece of the life science pie. Recently the commercial real estate firm Jones Lang LaSalle identified nine emerging regions: Minneapolis, Raleigh-Durham, Seattle, Chicago, Denver, Houston, Florida, Atlanta, and Indianapolis. While the first three are pretty established, a stronger case can be made for the rest as emerging clusters. As active as all have been, however, they remain overshadowed by San Francisco Bay Area as well as Boston and Cambridge. Do you think any of the newly identified regions will outpace its established rivals?